Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (131-140 of 271) with videos related to

Pageof 28
Sort By:
Cancer|June 24, 2006
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinomaNizar Tannir, Eric Jonasch, Lance C Pagliaro, et al.
The Journal of Urology|March 12, 2015
Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical NephrectomyArun Z Thomas, Mehrad Adibi, Leonardo D Borregales, et al.
BJU International|December 16, 2010
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinomaPatrick Schöffski, Jorge A Garcia, Walter M Stadler, et al.
Clinical Genitourinary Cancer|May 30, 2016
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell CarcinomaBrian I Rini, Yoshihiko Tomita, Bohuslav Melichar, et al.
Cancer|October 29, 2009
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysisEric Jonasch, Paul Corn, Lance C Pagliaro, et al.
Frontiers in Oncology|February 7, 2019
Sources of Frustration Among Patients Diagnosed With Renal Cell CarcinomaCristiane Decat Bergerot, Dena Battle, Paulo Gustavo Bergerot, et al.
Targeted Oncology|April 1, 2017
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell CarcinomaBrian I Rini, Victor Gruenwald, Eric Jonasch, et al.
Clinical Genitourinary Cancer|August 29, 2016
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With PazopanibMarc R Matrana, Ali Baiomy, Matthew Campbell, et al.
The Oncologist|April 1, 2021
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor TherapiesAndrew J Wiele, Tharakeswara K Bathala, Andrew W Hahn, et al.
Radiology|September 25, 2015
The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell CarcinomaNeema Jamshidi, Eric Jonasch, Matthew Zapala, et al.
Pageof 28

Showing results (131-140 of 271) with videos related to

Sort By:
Pageof 28
Cancer|June 24, 2006
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinomaNizar Tannir, Eric Jonasch, Lance C Pagliaro, et al.
The Journal of Urology|March 12, 2015
Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical NephrectomyArun Z Thomas, Mehrad Adibi, Leonardo D Borregales, et al.
BJU International|December 16, 2010
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinomaPatrick Schöffski, Jorge A Garcia, Walter M Stadler, et al.
Clinical Genitourinary Cancer|May 30, 2016
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell CarcinomaBrian I Rini, Yoshihiko Tomita, Bohuslav Melichar, et al.
Cancer|October 29, 2009
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysisEric Jonasch, Paul Corn, Lance C Pagliaro, et al.
Frontiers in Oncology|February 7, 2019
Sources of Frustration Among Patients Diagnosed With Renal Cell CarcinomaCristiane Decat Bergerot, Dena Battle, Paulo Gustavo Bergerot, et al.
Targeted Oncology|April 1, 2017
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell CarcinomaBrian I Rini, Victor Gruenwald, Eric Jonasch, et al.
Clinical Genitourinary Cancer|August 29, 2016
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With PazopanibMarc R Matrana, Ali Baiomy, Matthew Campbell, et al.
The Oncologist|April 1, 2021
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor TherapiesAndrew J Wiele, Tharakeswara K Bathala, Andrew W Hahn, et al.
Radiology|September 25, 2015
The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell CarcinomaNeema Jamshidi, Eric Jonasch, Matthew Zapala, et al.
Pageof 28